EC
MLYS icon

EntryPoint Capital’s Mineralys Therapeutics MLYS Stock Holding History

EntryPoint Capital’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,487
Closed -$154K – 849
2024
Q4 		$154K Buy
+12,487
New +$163K 0.06% 631
2024
Q3 		– Sell
-7,956
Closed -$93.1K – 937
2024
Q2 		$93.1K Buy
7,956
+3,324
+72% +$41.9K 0.14% 342
2024
Q1 		$59.8K Sell
4,632
-2,020
-30% -$24.9K 0.05% 669
2023
Q4 		$57.2K Buy
+6,652
New +$52.2K 0.05% 655

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

EntryPoint Capital's MLYS Position: Q1 2025 in Review

EntryPoint Capital sold out of Mineralys Therapeutics (MLYS) in Q1 2025, closing a stake of 12,487 shares — an estimated $154K sold.

EntryPoint Capital first reported a position in MLYS in Q4 2023 and held it in 4 quarters. The position peaked at $154K in Q4 2024. 149 funds tracked by Wall St. Rank hold MLYS as of Q1 2025.

  • EntryPoint Capital reported no remaining Mineralys Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 12,487 Mineralys Therapeutics shares in Q1 2025, an estimated $154K.
  • EntryPoint Capital first reported a position in Mineralys Therapeutics in Q4 2023 and held it in 4 quarters.
  • EntryPoint Capital's Mineralys Therapeutics position peaked at $154K in Q4 2024.
  • 149 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.